A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Start Date
4/6/2026
Completion Date
6/1/2027
Summary
The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.
Eligibility Criteria
Age Range: 18 years to 70 years
Interventions
ALKS 2680 Dose 1
ALKS 2680 Dose 2
Placebo
Conditions
Locations
Alkermes Investigational Site
Cullman, Alabama 35055
United States
Alkermes Investigational Site
Los Angeles, California 90025
United States
Alkermes Investigational Site
Boulder, Colorado 80301
United States
Alkermes Investigational Site
Brandon, Florida 33511
United States
Alkermes Investigational Site
Miami, Florida 33176
United States
Alkermes Investigational Site
Winter Park, Florida 32789
United States
Alkermes Investigational Site
Macon, Georgia 31210
United States
Alkermes Investigational Site
Kansas City, Kansas 66160
United States
Alkermes Investigational Site
Newton, Massachusetts 02459
United States
Alkermes Investigational Site
Lansing, Michigan 48911
United States
Alkermes Investigational Site
St Louis, Missouri 63123
United States
Alkermes Investigational Site
Middletown, New Jersey 07748
United States
Alkermes Investigational Site
Cincinnati, Ohio 45245
United States
Alkermes Investigational Site
Wyomissing, Pennsylvania 19610
United States
Alkermes Investigational Site
Columbia, South Carolina 29201
United States
Alkermes Investigational Site
Austin, Texas 78731
United States
Alkermes Investigational Site
San Antonio, Texas 78229
United States
Alkermes Investigational Site
Sugar Land, Texas 77478
United States
Alkermes Investigational Site
Macquarie Park, New South Wales 2113
Australia
Alkermes Investigational Site
Markham, Ontario L3R 1A3
Canada
Alkermes Investigational Site
Toronto, Ontario M5S 3A3
Canada
Alkermes Investigational Site
Zwolle, Overijssel 8011
Netherlands